Sign In
Buy BCDA
$0.82
+0.0531 (+6.89%)
At Close: Jul 31, 2026
BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript
08:44pm, Tuesday, 24'th Mar 2026
BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript
BioCardia Reports 2025 Business Highlights and Financial Results
04:05pm, Tuesday, 24'th Mar 2026
SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disea
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
07:47pm, Thursday, 19'th Mar 2026
SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
BioCardia (NASDAQ:BCDA) Stock Price Down 3.9% – Time to Sell?
02:20am, Thursday, 19'th Mar 2026
Shares of BioCardia, Inc. (NASDAQ: BCDA - Get Free Report) fell 3.9% on Wednesday. The company traded as low as $1.22 and last traded at $1.23. 42,279 shares traded hands during mid-day trading, a dec
SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA
08:00am, Tuesday, 16'th Dec 2025
SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress
08:30am, Monday, 01'st Dec 2025
SUNNYVALE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas
BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality
08:15am, Monday, 24'th Nov 2025
SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas
BioCardia, Inc. (BCDA) Q3 2025 Earnings Call Transcript
12:11am, Thursday, 13'th Nov 2025
BioCardia, Inc. ( BCDA ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Miranda Peto Benvenuti Peter Altman - CEO, President & Director David McClung - Chief Financial Office
BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results
04:40pm, Wednesday, 12'th Nov 2025
SUNNYVALE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025
07:29pm, Wednesday, 05'th Nov 2025
SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
BioCardia Regains Compliance with Nasdaq Listing Requirements
08:00am, Thursday, 02'nd Oct 2025
SUNNYVALE, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, a
BioCardia Announces Pricing of Up To $12 Million Public Offering
09:15am, Thursday, 18'th Sep 2025
$6 million upfront with up to an additional $6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants $6 million upfront with up to an additional $6 million of
SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
SUNNYVALE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- - BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease
